



12TH HTASIALINK CONFERENCE 2025 PRE-CONFERENCE PATIENT WORKSHOP

On 19 August 2025, as part of the 12th HTAsiaLink Conference 2025, the Agency for Care Effectiveness (ACE) and the Health Technology Assessment International (HTAi) Patient and Citizen Involvement in HTA Interest Group (PCIG) co-hosted a dynamic pre-conference patient workshop titled "**Voices to Action – The Value of Involving Patients in HTA**".



This workshop brought together around 100 participants from patient organisations, HTA agencies, healthcare and academic institutions, and industry across the Asia Pacific region. Participants learned about integrating patient preference evidence in HTA, explored case examples of patient involvement from different jurisdictions, and engaged in lively group discussions on barriers and enablers to meaningful patient engagement.



The vibrant exchanges and connections forged during the event highlighted the growing momentum in the region to ensure that patient voices are translated into tangible action within HTA processes. The shared insights were also brought to life through visual storytelling, captured in real time by talented graphic artist and patient advocate Ekawat Suwantaroj.

“ I can discuss with the other people from different countries or organisations. Learned so much! ”



“ Fantastic workshop! So encouraging to see all the amazing work happening across Asia. ”

“ I enjoyed how interactive the session was. I loved the group discussions and building off one another. ”



“ Knowing that the region shares best practices with each other and that patient involvement is getting more attention (was most useful) ”



We would like to express gratitude to all speakers and participants for contributing their invaluable insights to this important dialogue, as we work together to strengthen patient-centred approaches to healthcare decision-making in the Asia Pacific region.



CEE's booth at the HTAsiaLink Conference

The CEE team had a booth during the four-day conference, showcasing ACE's patient involvement processes, educational resources and learning modules. This provided a great opportunity to share our initiatives with international delegates and foster valuable connections.


SHARING ACE'S PATIENT INVOLVEMENT INITIATIVES INTERNATIONALLY, REGIONALLY AND LOCALLY



HTAi 2025 Annual Meeting, 14 to 18 June 2025


At a pre-meeting workshop led by HTAi PCIG titled "**Patient And Citizen Involvement: NextGen Participation to Achieve More Transparent, Equitable, And Fair Health Systems**", the CEE team shared Singapore's patient involvement experiences as a practical example. During the conference they also presented two abstracts, and the presentation materials are available on the [ACE website](#):

- **Oral presentation:** *Incorporating Lived Experiences in Health Technology Assessment: Impact on Subsidy Recommendations for Continuous Glucose Monitoring Systems in Singapore*
- **Poster:** *Tailored Health Technology Assessment Capacity Building: Co-designing Training Resources for Patients and Caregivers in Singapore*



Patient and Public Involvement and Engagement (PPIE) Community of Practice (COP) Meeting, 4 July 2025

This inaugural meeting gathered patient engagement professionals from healthcare and academia to discuss Singapore's patient engagement landscape. The CEE team shared about ACE's patient involvement efforts and our collaboration with the SingHealth Patient Advocacy Network (SPAN) in co-developing patient factsheets as a best practice example.



Taiwan HTA Patient Involvement Workshop, 6 August 2025

The CEE team shared Singapore's journey involving patients in HTA at a workshop organised by the Taiwan Young Patient Association to enhance meaningful patient involvement in Taiwan's HTA processes. The workshop was attended by representatives from Taiwan's Ministry of Health, HTA agency, patient groups and the industry.


PATIENT EDUCATION AIDS

1

Patient education aid published in August 2025

- Osteoporosis: Know the Facts **(new)**

Patient education aids are co-developed with patient organisations and clinicians to support the implementation of ACE Clinical Guidances by providing patients with basic and helpful information about different health conditions, treatments, medical tests and tips for better self-management.




Find out more



PLAIN ENGLISH SUMMARIES

NEW



14

Plain English summaries published since June 2025

Plain English summaries (PES) provide brief information about the treatments and conditions that have been evaluated by ACE and describe the key funding recommendations made by the MOH advisory committees.

Find out more




PUBLISHED PES

New:

- Asciminib for previously treated Philadelphia chromosome-positive chronic myeloid leukaemia
- Atogepant and rimegepant for preventing migraine
- Epcoritamab for previously treated relapsed or refractory diffuse large B-cell lymphoma
- Finerenone for treating chronic kidney disease and protein in the urine associated with type 2 diabetes
- Mavacamten for treating obstructive hypertrophic cardiomyopathy
- Tislelizumab for treating non-small-cell lung cancer without EGFR or ALK mutations

Updated:

- Anabolic drugs for treating osteoporosis
- Bevacizumab biosimilars for treating different types of cancer
- Chimeric antigen receptor T-cell therapies for relapsed or refractory large B-cell lymphoma
- Durvalumab in combination with tremelimumab for treating unresectable hepatocellular carcinoma
- Pembrolizumab for treating advanced HER2-positive gastric cancer
- Pembrolizumab for treating non-small-cell lung cancer before and after lung surgery
- Treatments for advanced malignant melanoma
- Treatments for advanced urothelial cancer



Read Here



VOICES TO IMPACT

The inaugural collection of impact stories titled "***Voices to Impact: How Involving Patients in Healthcare Decision-Making Makes a Difference***" has been published! From heart disease survivors to adults and children living with type 1 diabetes, discover how their lived experiences bring greater relevance and impact to healthcare decisions in Singapore.

This interactive flipbook was inspired by conversations with the ACE Consumer Panel, who highlighted the importance of sharing valuable patient insights. We will continue to expand our collection of patient and carer stories in this living document to demonstrate the value of patient voices in shaping better health outcomes.



THANK
YOU!

We would like to acknowledge all local patient organisations that have made invaluable contributions to ACE's work by sharing their expertise, insights, and lived experiences to help us develop our patient involvement processes.



Annual Call for Topics

The annual call for topics will be open from **October 2025 to January 2026**. Patients, carers and patient organisations will be invited to suggest which health technologies they would like ACE to evaluate. All patient organisations will receive an application form from the CEE team. Stay tuned for more details!



The Agency for Care Effectiveness (ACE) was established by the Ministry of Health (Singapore) to drive better decision-making in healthcare through health technology assessment (HTA), clinical guidance and education. The Consumer Engagement and Education (CEE) team supports patient involvement in ACE's work and co-develops plain English summaries and educational resources with patient organisations to improve health literacy and encourage shared healthcare decision-making between patients and their doctors. © Agency for Care Effectiveness, Ministry of Health, Republic of Singapore.

Published on 29 August 2025. To find out more about ACE, scan the QR code or visit www.ace-hta.gov.sg. You can also follow us on social media at:

